MedTrace Logo

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

NCT04106492 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-11-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

SQ3370

SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin

Sponsors & Collaborators

  • Shasqi, Inc.

    lead INDUSTRY

Principal Investigators

  • Jim Williams, MD · Shasqi, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2023-09-07
Completion
2023-09-07
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04106492 on ClinicalTrials.gov